Background Antiretroviral chemoprophylaxis before exposure is a promising approach for
the prevention of human immunodeficiency virus (HIV) acquisition. Methods We randomly …

Background Antiretroviral preexposure prophylaxis has been shown to reduce the risk of
human immunodeficiency virus type 1 (HIV-1) infection in some studies, but conflicting …

Background Antiretroviral preexposure prophylaxis is a promising approach for preventing
human immunodeficiency virus type 1 (HIV-1) infection in heterosexual populations …

Background Preexposure prophylaxis with antiretroviral drugs has been effective in the
prevention of human immunodeficiency virus (HIV) infection in some trials but not in others …

An estimated 56,000 human immunodeficiency virus (HIV) infections occur each year in the
United States. Men who have sex with men (MSM) account for 53% of the estimated incident …

Background Several recent clinical trials have shown that daily oral pre-exposure
prophylaxis (PrEP) with tenofovir disoproxil fumarate and emtricitabine (TDF–FTC) can …

Importance About 40 000 Americans and 2 million people worldwide are newly infected with
HIV each year. The combination antiretroviral regimen, tenofovir disoproxil fumarate …

Importance A 2019 review for the US Preventive Services Task Force (USPSTF) found oral
preexposure prophylaxis (PrEP) associated with decreased HIV infection risk vs placebo or …

Morbidity and mortality weekly report. 2012 Aug 10; 61 (31): 586-9. In the United States, an
estimated 48,100 new human immunodeficiency virus (HIV) infections occurred in 2009. Of …

Background Preexposure prophylaxis with antiretroviral agents has been shown to reduce
the transmission of human immunodeficiency virus (HIV) among men who have sex with …